05 Nov 2024 |
Loss of Share Certificate Intimation - P R Soma Sundaram & Somya Somasundram |
|
PDF 1.19 MB |
25 Oct 2024 |
Consolidation of Business in Europe |
|
PDF 598 KB |
25 Oct 2024 |
Newspaper Advertisement- Unaudited Financial Results for the quarter and half year ended September 30, 2024 |
|
PDF 1.16 MB |
24 Oct 2024 |
Loss of Share Certificate Intimation - M Premachandran Nair & Seema Nair |
|
PDF 1.01 MB |
24 Oct 2024 |
Outcome of Board Meeting – Un-Audited Financial Results (Standalone & Consolidated) for quarter and half year ended September 30, 2024 |
|
PDF 724 KB |
24 Oct 2024 |
Outcome of Board Meeting – Press Release & Earnings Presentation |
|
PDF 1.42 MB |
24 Oct 2024 |
Outcome of Board Meeting - Investment in AMPIN for captive consumption of Solar Energy |
|
PDF 286 KB |
24 Oct 2024 |
Outcome of Board Meeting –
Re-appointment of Dr. Kausalya Santhanam (DIN: 06999168) as Independent Director of the Company
|
|
PDF 388 KB |
23 Oct 2024 |
Loss of Share Certificate Intimation - Thankamony Joe & Joe Thomas |
|
PDF 1.01 MB |
23 Oct 2024 |
LOC - Rajagopalan J
|
|
PDF 351 KB |
17 Oct 2024 |
Loss of Share Certificate Intimation
|
|
PDF 1.05 MB |
16 Oct 2024 |
OneSource, the Group’s Spec Pharm CDMO, receives equity commitments of INR 8,010 mn (USD 95 mn) from marquee investors at a pre-money equity valuation of USD 1.65 bn
|
|
PDF 583 KB |
09 Oct 2024 |
Loss of Share Certificate Intimation
|
|
PDF 1.05 MB |
09 Oct 2024 |
Intimation under Reg 30 of SEBI LODR – Newspaper advertisement
|
|
PDF 3.31 MB |
08 Oct 2024 |
Strides’ Sustainability Report for FY24
|
|
PDF 9.51 MB |
07 Oct 2024 |
Loss of share certificate intimation - Krishnan P S and Geetha Krishnan
|
|
PDF 1.13 MB |
01 Oct 2024 |
Intimation under Regulation 30 of SEBI LODR
|
|
PDF 223 KB |
27 Sep 2024 |
Loss of share certificate intimation – K Dhana Lakshmi
|
|
PDF 614 KB |
27 Sep 2024 |
Outcome of 33rd Annual General Meeting of the Company
|
|
PDF 902 KB |
26 Sep 2024 |
Corporate Deck of OneSource
|
|
PDF 3.51 MB |
25 Sep 2024 |
Intimation under Regulation 30 of SEBI LODR
|
|
PDF 440 KB |
17 Sep 2024 |
Intimation regarding receipt of Order from Reserve Bank of India, Foreign Exchange Department,
Mumbai.
|
|
PDF 544 KB |
16 Sep 2024 |
Strides receives USFDA approval for Fluoxetine Tabs 60 mg; Expanding the Product’s Availability
Across Strengths
|
|
PDF 432 KB |
12 Sep 2024 |
Update on Scheme of Amalgamation of Strides Alathur Private Limited (formerly known as Vivimed
Life Sciences Private Limited) into the Company.
|
|
PDF 227 KB |
11 Sep 2024 |
Press Release - Approval from Equity Shareholders and Secured Creditors
|
|
PDF 513 KB |
11 Sep 2024 |
Voting Results - NCLT Convened Meetings – Sept 11, 2024
|
|
PDF 6.75 MB |
10 Sep 2024 |
Proceedings of NCLT Convened Meetings – Sept 10, 2024
|
|
PDF 630 KB |
06 Sep 2024 |
Intimation under Regulation 30 of SEBI LODR
|
|
PDF 216 KB |
06 Sep 2024 |
Strides receive USFDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg
|
|
PDF 463 KB |
02 Sep 2024 |
Notice of the 33rd Annual General Meeting and Annual Report for FY 2023-24
|
|
PDF 6.81 MB |
28 Aug 2024 |
Intimation under Regulation 30 of SEBI LODR
|
|
PDF 325 KB |
22 Aug 2024 |
Intimation pursuant to Regulation 31A
|
|
PDF 378 KB |
22 Aug 2024 |
AGM_Intimation of Record Date
|
|
PDF 286 KB |
19 Aug 2024 |
EIR from USFDA on continued GMP status for the facility in Alathur, Chennai
|
|
PDF 211 KB |
14 Aug 2024 |
Intimation under Regulation 30 of SEBI LODR
|
|
PDF 333 KB |
14 Aug 2024 |
Pronouncement of Order by NCLT regarding Scheme of Amalgamation of Strides Alathur
|
|
PDF 268 KB |
09 Aug 2024 |
Notice of meetings - Eq shareholders and Secured Creditors
|
|
PDF 548 KB |
09 Aug 2024 |
Intimation under Reg 30 of SEBI LODR – Newspaper advertisement
|
|
PDF 6.78 MB |
05 Aug 2024 |
Acquisition of balance stake in Strides Global Consumer Healthcare Limited, UK
|
|
PDF 310 KB |
30 Jul 2024 |
Intimation under Regulation 30 of SEBI LODR
|
|
PDF 269 KB |
30 Jul 2024 |
Update on Scheme of Arrangement amongst Strides Pharma Science Limited and Steriscience
Specialties Private Limited and Onesource Specialty Pharma Limited
(formerly known as Stelis Biopharma Limited) and their respective shareholders, under Section 230 to
232 of the Companies Act, 2013.
|
|
PDF 290 KB |
30 Jul 2024 |
Newspaper Advertisement-Unaudited Financial Results for the quarter ended June 30, 2024
|
|
PDF 1.00 MB |
29 Jul 2024 |
Voting Results of Postal Ballot pursuant to Reg. 44 of SEBI Listing Regulations
|
|
PDF 1.89 MB |
29 Jul 2024 |
Outcome of Board Meeting – Un-Audited Financial Results (Standalone & Consolidated) for quarter
ended June 30, 2024
|
|
PDF 634 KB |
29 Jul 2024 |
Outcome of Board Meeting – Press Release & Earnings Presentation
|
|
PDF 1.29 MB |
29 Jul 2024 |
Outcome of Board Meeting - Allotment of Shares
|
|
PDF 289 KB |
29 Jul 2024 |
Outcome of Board Meeting - Intimation pursuant to Board approval for Promoter Reclassification
|
|
PDF 555 KB |
27 Jul 2024 |
Incorporation of Step-down Wholly Owned Subsidiary in New Zealand
|
|
PDF 304 KB |
26 Jul 2024 |
Loss of share certificate intimation
|
|
PDF 362 KB |
24 Jul 2024 |
Request for Promoter/ Promoter Group Reclassification
|
|
PDF 786 KB |
23 Jul 2024 |
Intimation under Reg 39 (3) of LODR – Leela Tathi
|
|
PDF 329 KB |
16 Jul 2024 |
Intimation under Reg 39 (3) of LODR – Sriram Shankar
|
|
PDF 333 KB |
27 Jun 2024 |
Newspaper Advertisement – Notice of Postal Ballot dated May 22, 2024
|
|
PDF 1.33 MB |
26 Jun 2024 |
Notice of Postal Ballot dated May 22, 2024
|
|
PDF 735 KB |
16 Jun 2024 |
Intimation under Reg 39 (3) of LODR – Vibhishanan V
|
|
PDF 2.55 MB |
14 Jun 2024 |
Intimation under Regulation 30 of SEBI LODR
|
|
PDF 270 KB |
23 May 2024 |
Newspaper Advertisement – Audited Financial Results for quarter and financial year ended March 31,
2024
|
|
PDF 1.28 MB |
22 May 2024 |
Observation Letters from BSE & NSE
|
|
PDF 2.06 MB |
22 May 2024 |
Disposal of Corporate Insolvency Process against Strides Alathur Private Limited
|
|
PDF 346 KB |
22 May 2024 |
Outcome of Board Meeting – Audited Financial Results (Standalone & Consolidated) for quarter and
year ended March 31, 2024 & Recommendation of Dividend
|
|
PDF 4.89 MB |
22 May 2024 |
Outcome of Board Meeting – Press Release & Earnings Presentation
|
|
PDF 1.54 MB |
22 May 2024 |
Outcome of Board Meeting – Change in Board composition and Management
|
|
PDF 376 KB |
22 May 2024 |
Outcome of Board Meeting - Allotment of Shares
|
|
PDF 288 KB |
22 May 2024 |
Outcome of Board Meeting - Grant of ESOP
|
|
PDF 295 KB |
22 May 2024 |
Strides receives USFDA approval for Sucralfate Oral Suspension, 1gm/10 mL
|
|
PDF 444 KB |
21 May 2024 |
Intimation under Reg 39 (3) of LODR – Rajagopalan J
|
|
PDF 713 KB |
10 May 2024 |
Strides receives USFDA approval for Sevelamer Carbonate Tablets, 800 mg
|
|
PDF 1.11 MB |
06 May 2024 |
Intimation under Reg 39 (3) of LODR – K Murali
|
|
PDF 730 KB |
30 Apr 2024 |
Voting Results of Postal Ballot pursuant to Reg. 44 of SEBI Listing Regulations – Appointment of
Mr. Ameet P Hariani (DIN: 00087866) as Independent Director of the Company |
|
PDF 2.35 MB |
29 Apr 2024 |
Intimation under Regulation 30 of SEBI Regulations, 2015 (Allotment of shares) |
|
PDF 749 KB |
09 Apr 2024 |
Strides receives USFDA approval for Fluoxetine Tabs 10 mg and 20 mg |
|
PDF 455 KB |
06 Apr 2024 |
Completion of US-FDA Inspection at the Formulations Facility of Strides Alathur Private Limited, a
wholly owned subsidiary of the Company |
|
PDF 249 KB |
29 Mar 2024 |
Newspaper Advertisement - Notice of Postal Ballot dated March 27, 2024 |
|
PDF 1.00 MB |
28 Mar 2024 |
Outcome of Appeal at Hon’ble National Company Law Appellate Tribunal, New Delhi – Corporate
Insolvency Process against Strides Alathur stands stayed |
|
PDF 260 KB |
28 Mar 2024 |
Notice of Postal Ballot dated March 27, 2024 |
|
PDF 586 KB |
26 Mar 2024 |
Intimation under Regulation 30 of SEBI LODR regarding Strides Alathur |
|
PDF 320 KB |
18 Mar 2024 |
Intimation under Reg 39 (3) of LODR - Venkat Seetharama Rao Teegala |
|
PDF 318 KB |
08 Mar 2024 |
Newspaper Publication – Hearing of Petition in the matter of Scheme of Amalgamation between
Strides Alathur Private Limited and the Company |
|
PDF 2.61 MB |
05 Mar 2024 |
Strides receives USFDA approval for Gabapentin Tablets USP, 600 mg and 800 mg |
|
PDF 596 KB |
02 Feb 2024 |
Intimation under Regulation 30 of SEBI LODR – Investors Presentation |
|
PDF 2 MB |
02 Feb 2024 |
Intimation under Regulation 30 of SEBI LODR – Update on divestment of Eris Pharma GmbH, Germany
|
|
PDF 252 KB |
31 Jan 2024 |
Newspaper Advertisement – Unaudited Financial Results for quarter and nine months ended December
31, 2023 |
|
PDF 1.22 MB |
30 Jan 2024 |
Outcome of Board Meeting – Unaudited Financial Results (Standalone & Consolidated) for quarter and
nine months ended December 31, 2023 |
|
PDF 642 KB |
30 Jan 2024 |
Strides reports strong Q3FY24 Revenue and EBITDA |
|
PDF 1.63 MB |
30 Jan 2024 |
Appointment of Mr. Ameet P Hariani as Independent Director of the Company |
|
PDF 275 KB |
30 Jan 2024 |
Intimation under Regulation 30 of SEBI Listing Regulations – Corporate Guarantees on behalf of
Stelis |
|
PDF 394 KB |
30 Jan 2024 |
Allotment of Shares |
|
PDF 284 KB |
25 Jan 2024 |
Strides receives USFDA approval for Pregabalin Capsules |
|
PDF 404 KB |
23 Jan 2024 |
Intimation under Reg 39 (3) of LODR - Haresh Dave & Karesh Dave |
|
PDF 711 KB |
11 Jan 2024 |
Intimation under Regulation 30 of SEBI LODR – Divestment of Eris Germany |
|
PDF 432 KB |
08 Jan 2024 |
Intimation under Reg 39 (3) of LODR - Geeta K Doshi |
|
PDF 878 KB |
08 Jan 2024 |
Intimation under Reg 39 (3) of LODR - Krishna Kishore Busetty |
|
PDF 475 KB |
05 Jan 2024 |
Intimation under Regulation 30 of SEBI LODR – Acquisition of additional stake in Neviton |
|
PDF 346 KB |
02 Jan 2024 |
Intimation under Regulation 30 of SEBI LODR – Investment in AMP Energy |
|
PDF 300 KB |